ArticleEndocrine2025
"Radioactive iodine therapy in low-risk pediatric thyroid cancer: universal standard or selective indication?"
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioactive iodine (RAI) treatment in low-risk pediatric patients with differentiated thyroid cancer (DTC) is still debatable. The objective of this study is to evaluate the outcome of treated and untreated patients in pediatric age. The data of all pediatric patients affected by low-risk category DTC according to ATA (American Thyroid Association) during the period 2010-2024 were reviewed. Patients with DTC dimensions > 2 cm and/or lymph node involvement underwent to RAI. In our cohort 7/14 (50%) of subjects were treated with RAI. Cytological categories after FNAB were TIR3b in 2/7 (28.6%) and TIR5 in 5/7 (71.4%) for RAI-treated patients, whereas TIR3b was observed in 6/7 (85.7%) and TIR5 in 1/7 (14.3%) in untreated patients (p = 0.03). T1 stage was assigned in 1/7 (14.3%) of patient treated with RAI, T2 stage was present in the remaining 6/7 (85.7%), whereas T 1 stage was observed in 6/7 (85.7%) and T2 stage in 1/7 (14.3%) of untreated patients (p = 0.007). No difference was observed regarding disease persistence or recurrence between treated and untreated patients. Considering the young age, a case-by-case approach may be reasonable in subjects assigned to the low-risk category, rather than absolute recommendation for all pediatric patients with DTC.
Indexed as
Identifiers
40410630What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.